Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (39)

2024

  1. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up

    Dermatitis, Vol. 35, pp. S55-S61

  2. Real-World Safety and Efficacy Profile of Baricitinib in Patients With Atopic Dermatitis: a Multicenter Retrospective Trial From Four Spanish Hospitals in Andalusia

    Actas Dermo-Sifiliograficas

  3. [Translated article] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

2023

  1. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  2. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study

    Actas Dermo-Sifiliograficas

  3. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

  4. Upadacitinib for moderate to severe atopic dermatitis

    Immunotherapy, Vol. 15, Núm. 11, pp. 799-808

2022

  1. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

    Life

  2. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

  3. Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study

    F1000Research, Vol. 11

  4. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

    Dermatologic Therapy, Vol. 35, Núm. 10

  5. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab

    Dermatologic Therapy, Vol. 35, Núm. 11

  6. Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review

    Life, Vol. 12, Núm. 8

  7. Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

    Life, Vol. 12, Núm. 11

  8. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series

    International Journal of Dermatology, Vol. 61, Núm. 8, pp. 1029-1033

  9. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)

    Journal of Clinical Medicine, Vol. 11, Núm. 17

  10. Tildrakizumab: short-term efficacy and safety in real clinical practice

    International Journal of Dermatology

  11. Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning

    International journal of environmental research and public health, Vol. 19, Núm. 17

2021

  1. 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain

    Anais Brasileiros de Dermatologia, Vol. 96, Núm. 6, pp. 787-790

  2. Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study

    British Journal of Dermatology